Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Nautilus Biotechnology to post earnings of ($0.17) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the previous year, the firm posted ($0.13) earnings per share. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nautilus Biotechnology Stock Down 1.1 %
NAUT opened at $2.69 on Friday. The stock has a market cap of $336.96 million, a PE ratio of -4.89 and a beta of 1.22. The business has a 50 day moving average of $2.73 and a 200-day moving average of $2.61. Nautilus Biotechnology has a 52 week low of $2.19 and a 52 week high of $3.45.
Insider Activity
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Featured Articles
- Five stocks we like better than Nautilus Biotechnology
- Consumer Discretionary Stocks Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Golden Cross Stocks: Pattern, Examples and Charts
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.